Ghrelin is a brain-gut peptide that serves as a natural ligand for growth hormone secretagogue receptor (GHSR). It also exists abundantly in the cardiovascular system. In order to evaluate the possible role of ghrelin in the development of atherosclerosis, the effect of ghrelin on the expression of cell differentiation antigen 40 (CD40) were studied. Human umbilical vein endothelial cell (HUVEC) line-ECV 304 was pretreated with different concentrations of ghrelin, des-acyl ghrelin or [d-Lys]-GHRP-6 (a ghrelin receptor antagonist), and then induced with tumor necrosis factor-α (TNF-α) and interferon γ (IFN-γ). The mRNA levels of CD40 were analyzed by reverse transcription-polymerase chain reaction, and the expressions of CD40 protein in the cells were measured by flow cytometry (FCM) and Western blotting. The results showed that exogenous ghrelin could significantly inhibit TNF-α/IFN-γ induced CD40 expression in HUVEC cells in a concentration-dependent manner. When treated with 1000 ng/ml of ghrelin, the mRNA level of CD40 in the cells was decreased by approximately 77%, but when treated with both 1000 ng/ml of ghrelin and 1000 ng/ml of [d-Lys]-GHRP-6, the mRNA level of CD40 in the cells was decreased by only 42%, suggesting that [d-Lys]-GHRP-6 could counteract the inhibitory effect of ghrelin in these cells. However, CD40 expression was not inhibited by des-acyl ghrelin at 1000 ng/ml. The results in protein expression analysis detected by FCM and Western blotting further confirmed these results. Our results suggested that in the cardiovascular system, ghrelin not only has an anti-inflammatory effect, but also has a significant immunoregulatory effect that may be mediated through the GHSR-1a receptor.
Ghrelin is a brain-gut peptide discovered by Kojima et al. in 1999 . To date, it is the only natural ligand for growth hormone releasing hormone receptor [1] . It was reported that, after binding with its receptor, ghrelin not only promotes the release of growth hormone (GH), but also regulates energy metabolism and plays a vital role in various diseases and physiological processes.
Ghrelin is not only expressed in stomach tissue, but also distributed abundantly in the cardiovascular system, suggesting that ghrelin and its receptor might play a vital role there. Then what is the role of ghrelin and its receptor in the pathogenesis of atherosclerosis? A study by Katugampola et al. showed that density of ghrelin receptor is higher in the cardiovascular system of atherosclerotic mice than in that of normal controls, indicating that ghrelin and its receptor are possible potential targets of treatment in cardiovascular disease [2] . Chang et al. found that ghrelin can markedly increase blood flow in mice with ischemia and reperfusion injury [3] . Western blot analysis showed that ghrelin improved endothelial function by increasing the expression of nitric oxide synthase, independent of the release of GH [4] . Ghrelin was also proved to be an endogenic antagonist of endothelin [5] . Hexarelin, a GH-releasing peptide, might enhance cholesterol efflux in macrophages. These effects were associated with a transcriptional activation of nuclear receptor peroxisome proliferator-activated receptor (PPAR) gamma in response to the binding of hexarelin to GH secretagogue receptor (GHSR) 1a, the receptor for ghrelin [6] . Another important finding indicated that ghrelin http://www.abbs.info; www.blackwellpublishing.com/abbs reversed endothelial dysfunction in patients with metabolic syndrome by increasing nitric oxide bioactivity, suggesting that ghrelin might play a role in the pathobiology of atherosclerosis [7] . Recent research also showed the antiinflammatory effect of ghrelin in the cardiovascular system. Skilton et al. found that ghrelin can up-regulate the expression of molecules such as ICAM-1, VCAM-1, and E-selectin in human umbilical vein endothelial cells (HUVECs) [8] . Exogenic ghrelin might inhibit TNF-α-induced release of inflammatory factors in HUVECs, with the implication of possible involvement of ghrelin in the regulation of the inflammatory process of atherosclerosis [9] .
Many studies support the idea that atherosclerosis is a kind of chronic inflammatory disease connected with the immune system. We already know that interaction between CD40 and its ligand (CD40L) is involved in the development of atherosclerosis [10] . CD40 and CD40L exist extensively in various cells of atheromatous plaque, suggesting that they not only play a vital role in immune reactions, but also are closely related with the development and stability of plaque [11, 12] . CD40L-CD40 interactions induce an up-regulation of adhesion molecules, inflammatory cell chemotatic factor, matrix metalloproteinase, and tissue factor expression. Moreover, CD40 ligation induces fibroblast activation and proliferation. It is believed that the CD40/CD40L pathway might play important roles in the pathogenesis and development of atherosclerosis, as well as in plaque rapture and subsequent thrombosis formation [13−16] . Animal experiments showed that CD40L might inhibit the process of atherosclerosis and stabilize the plaques, and also implied the significance of the CD40/CD40L system in diseases related to atherosclerosis [17] .
No report has yet described whether ghrelin can intervene in the CD40/CD40L system, further inhibit inflammation and thrombosis, and delay the progress of atherosclerosis. This study was designed to observe the effect of exogenous ghrelin intervention in HUVECs on CD40 expression in the cells, and elucidate the effect of the ghrelin system on the development of atherosclerosis.
Materials and Methods

Materials
Ghrelin, des-acyl ghrelin, and ghrelin receptor selective antagonist [d-Lys]-GHRP-6 were obtained from Phoenix Pharmaceuticals (Burlingame, USA). HUVEC cell line ECV-304 was from the Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Science, Chinese Academy of Sciences (Shanghai, China). Recombinant human TNF-α and FITC-conjugated mouse anti-human CD40 monoclonal antibody were from BD Biosciences (San Jose, USA). Recombinant human IFN-γ was from PeproTech (Rocky Hill, USA). Trizol and diethyl pyrocarbonate (DEPC) were purchased from Gibco-BRL Life Technologies (Grand Island, USA). 3-N-Morpholinopropane sulfonic acid (MOPS), Moloney murine leukemia virus (M-MLV) reverse transcriptase, random primer, dNTP, and DNA marker (50−1000 bp) were purchased from Promega (Fitchburg, USA). Taq enzyme was from Biostar International (Toronto, Canada). Western blotting reagent kit and enhanced chemiluminescence reagent kit were from Hoffman-La Roche (Vienna, Austria). Rabbit anti-human CD40 antibody was from Santa Cruz Biotechnology (Santa Cruz, USA). Horseradish peroxidaseconjugated goat anti-rabbit immunoglobulin G(H+L) was from KPL (Gaithersburg, USA)
Culture and intervention of ECV-304 cells
ECV-304 cells were seeded in 6-well plates and cultured for 24−48 h in RPMI 1640 medium containing 10% fetal bovine serum (FBS) at 37 ºC, in 5% CO 2 . Growth of cells was observed by microscope and 50%-80% confluence was found.
Complete culture medium was substituted with RPMI 1640 medium without FBS and cells were further incubated in 5% CO 2 at 37 ºC overnight. Cells were then treated with TNF-α, IFN-γ or TNF-α and IFN-γ at various concentrations for 6, 9, 12, 15, 18, 20, or 24 h in RPMI 1640 medium without FBS. Phosphate-buffered saline (PBS) in the same quantity was taken as the negative control. Cells were collected for the subsequent analyses.
Complete culture medium was substituted with RPMI 1640 medium without FBS, and cells were incubated in 6-well plates with control medium, ghrelin (10, 100 or 1000 ng/ml), des-acyl ghrelin (1000 ng/ml), or ghrelin (1000 ng/ml) and [d-Lys]-GHRP-6 (1000 ng/ml) in RPMI 1640 medium without FBS for 1 h at 37 ºC. Then TNF-α (100 U/ml) and IFN-γ (1500 U/ml) were added, and cells were further cultured in 5% CO 2 at 37 ºC for 9 or 20 h. Cells were collected for the subsequent analyses.
Reverse transcription-polymerase chain reaction (RT-PCR)
ECV-304 cells with different interventions were collected and washed with PBS. Total RNA was extracted from cells using the single-step guanidinium thiocyanate method [18] . Two micrograms of total RNA was used for RT in a total volume of 10 μl containing 2 μg RNA, 0.5 μl random primer, 1 μl Rnasin and DEPC-treated water. The mixture was incubated at 65 ºC for 5 min, then put on ice. One microliter of Moloney murine leukemia virus (200 U/μl), 4 μl buffer solution, 1 μl of 10 mM dNTP, and DEPC were added and incubated at 37 ºC for 1 h and reverse transcriptase inactivated at 95 ºC for 5 min. cDNA was used for PCR. Primers of CD40 and β-actin were designed according to Krzesz et al. [19] , and synthesized by Shanghai Biology Engineering Inc. (Shanghai, China). The sense and antisense primers for the CD40 gene were 5′-CAGAGTTCACTGAAACGGAATGCC-3′ and 5′-TGCCTGCCTGTTGCACAACC-3′ (amplification product 380 bp), respectively. The cycling conditions were 94 ºC for 4 min, followed by 28 cycles of 94 ºC for 30 s, 62 ºC for 45 s, 72 ºC for 1 min, and a final extension of 72 ºC for 10 min. The sense and antisense primers for β-actin were 5′-AAGGATTCCTATGTGGGC-3′ and 5′-CATCTCTTGCTCGAAGTC-3′ (amplification product 532 bp), respectively. The cycling conditions were 94 ºC for 4 min, followed by 35 cycles of 94 ºC for 30 s, 55 ºC for 45 s, 72 ºC for 1 min, and a final extension of 72 ºC for 10 min. PCR products were separated on a 1.3% agarose gel and viewed by ethidium bromide staining. Density quantification of the electrophoresis strip was carried out by gel scanning software (UVP, Upland, USA) to analyze the electrophoresis strip density ratio in each sample of target fragment to β-actin.
Detection of CD40 protein expression by flow cytometry
ECV-304 cells with different interventions were collected and washed with PBS. FITC-conjugated mouse anti-CD40 monoclonal antibodies (10 μl) were added to the cells in each tube, then incubated at 4 ºC for 30 min. Unbound antibodies were washed away with PBS and cells were resuspended in 200 μl PBS, fixed with 1% paraformaldehyde and analyzed by flow cytometry. Ten thousand cells were collected and analyzed by CellQuest software (Version 3.0; Becton Dickinson Immunocytometry Systems, San Jose, USA) and mean fluorescence intensity was calculated.
Detection of CD40 protein expression by Western blot analysis
Cells were lysed in PBS buffer (pH 7.4) containing 0.6% NP-40, 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate, 50 mg/ml aprotinin, 100 mg/ml phenylmethyls ulfonyl fluor ide, 1 mM sodium orthovanadate, and 50 mM sodium fluoride. Cell lysates were centrifuged at 10,000 g for 15 min at 4 ºC, and the protein concentration in the supernatants was determined using a BCA protein assay kit (Pierce, Rockford, USA). Samples containing 10 μg protein were boiled for 10 min and subjected to 8% SDS-PAGE, then transferred to the PVDF membranes. After blocking and washing, membranes were incubated with rabbit anti-human CD40 antibody (1:100) overnight at 4 ºC and further incubated for 1 h with horseradish peroxidase-conjugated goat antirabbit immunoglobulin G (1:5000). Bound antibodies were detected with an enhanced chemiluminescence kit. Membranes were then washed in washing buffer (Trisbuffered saline containing 0.1% Tween 20) with shaking at 50 ºC for 30 min to remove the antibody. Western blot analysis was carried out using the same method, displaying the corresponding β-actin band, which was used as the internal control for the protein expression of the sample. Density of bands was evaluated by an image analysis system (Bio-Rad, Hercules, USA) and quantitative analysis was carried out. Quantity of protein was expressed by the density ratio [20] .
Statistical analysis
Each experiment was repeated three times. SAS software 9.0 (SAS, Cary, USA) was used for statistical analysis and data were expressed as the mean±SD. Comparison between measurement data used the Student's t-test or single factor analysis of variance, and differences were considered statistically significant at P<0.05.
Results
Expression of CD40 induced by cytokines
Without intervention of a stimulant, HUVECs had low levels of CD40 expression. A single application of TNF-α or IFN-γ mildly increased CD40 expression in endothelial cells. Combined application of TNF-α (100 U/ml) and IFN-γ (1500 U/ml) stimulated cells. Then mRNA expression of CD40 was detected at 6, 9, and 12 h. mRNA expression of CD40 in the TNF-α/IFN-γ intervention group was significantly higher than that of the control groups, peaking at 9 h after TNF-α/IFN-γ stimulation. Its relative density of CD40 was 231.75%±12.44%, whereas the value in the control group was 81.52%±7.45%, P<0.01 (Fig. 1) . Combined application of TNF-α and IFN-γ also increased the protein expression of CD40 in endothelial cells. Expression of CD40 protein reached its peak 20 h after stimulation. The CD40 mean fluorescence intensity value http://www.abbs.info; www.blackwellpublishing.com/abbs (A) (B) in the stimulation group after 20 h was 14.83±0.68, whereas the value in the control group was 11.96±0.43, P<0.01 (Fig. 2) .
Effect of ghrelin on mRNA of CD40 in endothelial cells
Ghrelin down-regulated TNF-α/IFN-γ-induced CD40 expression in a dose-dependent manner. Increased concentration of ghrelin significantly down-regulated CD40 expression. When the concentration of ghrelin was 1000 ng/ml, the mRNA level of CD40 was at its lowest level, and the relative density decreased by 77% (from 98.66%± 7.7% to 22.45%±7.41%, P<0.01). Des-acyl ghrelin had no significant inhibitory effect on TNF-α/IFN-γ-induced mRNA expression of CD40, P>0.05. When treated with both ghrelin (1000 ng/ml) and [d-Lys]-GHRP-6 (1000 ng/ml), the mRNA level of CD40 in the cells was decreased by only 42% (from 98.66%±7.7% to 57.64%±6.28%, P<0.01), suggesting that [d-Lys]-GHRP-6 could significantly counteract the inhibitory effect of ghrelin on TNF-α/IFN-γ-induced mRNA expression of CD40 (Fig. 3) .
Increased concentration of [d-Lys]-GHRP-6 increased the inhibition effect on ghrelin (data not shown).
Effect of ghrelin on CD40 protein expression in endothelial cells
At the protein level, flow cytometry showed that ghrelin (Fig. 4) . Western blot analysis was also used to examine the effect of ghrelin on the protein expression of CD40, and the same results were produced. Ghrelin decreased TNF-α/IFN-γ-induced protein expression of CD40 in a dose-dependent manner. When the concentration of ghrelin was 1000 ng/ml, the CD40 protein was at its Fig. 3 Effect
of ghrelin (G) at different concentrations, des-acyl ghrelin (des-G), and ghrelin+ghrelin receptor selective antagonist [d-Lys]-GHRP-6 (anta-G) on CD40 mRNA expression induced by TNF-α/IFN-γ
Human umbilical vein endothelial cells (ECV-304) were pre-incubated in 6-well plates with blank control, exogenous G (10, 100, or 1000 ng/ml), des-G (1000 ng/ ml), or anta-G (1000 ng/ml) added separately for 1 h. Cells were then exposed to TNF-α (100 U/ml) and IFN-γ (1500 U/ml) (T/I) for 9 h. RT-PCR was used to assess CD40 expression. (A) CD40 mobility spectrum. 1, control; 2, T/I; 3, T/I+G 10 ng/ml; 4, T/I+G 100 ng/ml; 5, T/I+G 1000 ng/ml; 6, T/I+des-G; 7, T/I+G+anta-G. (B) Summary of averaged relative density units in three independent experiments. *P<0.05 compared with control; # P<0.05 compared with T/I. M, DNA maker.
Fig. 4 Effect of ghrelin (G) at different concentrations, des-acyl ghrelin (des-G), and ghrelin+ghrelin receptor selective antagonist [d-Lys]-GHRP-6 (anta-G) on CD40 protein expression induced by TNF-α/IFN-γ detected by Flow cytometry analysis
Human umbilical vein endothelial cells (ECV-304) were pretreated with G (10, 100, or 1000 ng/ml), des-G (1000 ng/ml), or G+anta-G (1000 ng/ml) for 1 h, then exposed to TNF-α (100 U/ml) and IFN-γ (1500 U/ml) (T/I) for 20 h. 
Discussion
In this study, HUVECs were used to observe the direct action of cytokines on endothelial cells, then observe CD40 expression. The results proved that cultured HUVECs showed little CD40 expression without the intervention of a stimulant. However, cytokines TNF-α and IFN-γ could up-regulate expression mildly when used separately, and significantly up-regulate it when used together. This is consistent with the conclusions drawn by Wagner et al. [21] . Another study found that the combined application of these two cytokines significantly up-regulated CD40 expression in mouse vascular smooth muscle cells and macrophages, suggesting that TNF-α (by transcription factor NF-κB) and IFN-γ (by transcription factor activated protein AP-1 or transcriptional activator STAT-1) induced CD40 expression in smooth muscle cells and macrophages. They concluded that application of these two stimulants could produce a combined effect on those two transcription factors and further improve CD40 expression significantly [22] . However, CD40 can activate endothelial cells by interacting with CD40L, inducing an inflammatory reaction in the vascular walls and thus initiating atherosclerosis. Recent studies showed that ghrelin has some inflammationregulating effects in the cardiovascular system. Skilton et al. [8] used ghrelin to intervene HUVECs and found that it could significantly up-regulate the expression of intercellular adhesion molecules such as E-selectin, ICAM-1, and VCAM-1. Li et al. [9] also reported that release of inflammatory factors and up-regulation of NF-κB caused by TNF-α could be inhibited by exogenous ghrelin in HUVECs. Also, in vivo murine experiments showed that ghrelin had a similar inhibitory effect on inflammation induced by endotoxin, suggesting ghrelin has a regulating effect on the inflammatory reaction in the pathogenesis of atherosclerosis [6] . However, it has not been reported whether ghrelin has a regulating effect on the CD40/ CD40L system and whether the mechanism is similar to its regulating effect on inflammation.
For the first time, this study showed that exogenous ghrelin could significantly inhibit the combined TNF-α and IFN-γ-induced CD40 expression in HUVECs in a dosedependent manner. This result suggests that the effect of ghrelin intervention on the CD40/CD40L system might be one of its immune-regulating mechanisms. Two subtypes of ghrelin receptors, GHSR-1a and GHSR-1b, have already been identified [1] . It was reported that the activated form of ghrelin uses an acetylation structure and this structure Human umbilical vein endothelial cells (ECV-304) were pretreated with G (10, 100, or 1000 ng/ml), des-G (1000 ng/ml), or anta-G (1000 ng/ml) for 1 h, then exposed to TNF-α (100 U/ml) and IFN-γ (1500 U/ml) (T/I) for 20 h. Representative blots of CD40 protein (A1) and β-actin (A2). 1, T/I; 2, T/I+G 10 ng/ml; 3, T/I+G 100 ng/ml; 4, T/I+G 1000 ng/ml; 5, T/I+des-G; 6, T/I+G+anta-G. (B) Summary of averaged relative density units in three independent experiments. *P<0.05 compared with T/I; #P<0.05 compared with T/I+G 1000 ng/ml.
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can bind with GHSR-1a to produce its endocrine physiological function. The physiological function of GHSR-1b is not known yet. Li et al. [9] found that ghrelin could inhibit TNF-induced cytokine release of HUVECs and NF-κB activity, and that its anti-inflammatory effect was realized after it was acetylated and acted on GHSR-1a. Des-acyl ghrelin, the isomer of ghrelin, exists abundantly in the serum but is unable to bind with its receptor. Therefore, it has no endocrine or inflammatory effect. However, recent studies have shown that ghrelin and desacyl ghrelin have some of the same physiological functions, such as anti-apoptotic and antilipolytic effects, and these effects can be fulfilled through binding with other unknown receptors [23, 24] .
To further explore whether the effect of ghrelin (inhibiting CD40 expression in HUVECs induced by cytokine) is found when it is combined with its known receptor GHSR-1a, this study repeated the experiment with des-acyl ghrelin, a ghrelin isomer, and found that it did not have the same effect as ghrelin (i.e., could not inhibit CD40 expression induced by cytokines). As we know that des-acyl ghrelin can not combine with the GHSR-1a receptor, it can be speculated that the effect of ghrelin on the CD40/CD40L system depends on the GHSR-1a receptor, and this is in accord with the antiinflammatory mechanism of ghrelin [9] . To further identify the mechanism, this study used the selective antagonist of GHSR-1a receptor, [d-Lys]-GHRP-6 [25] , and found that it significantly blocked the inhibitory effect of ghrelin on CD40 expression and was concentration-dependent. Therefore, [d-Lys]-GHRP-6 might exert its effect by competing with ghrelin as a binding site for ghrelin receptor. Hence, the immune regulating effect and antiinflammatory effect of ghrelin in inhibiting CD40 expression was realized through combining with a known GHSR-1a receptor.
In summary, this study proved for the first time by cytology that exogenous ghrelin could significantly inhibit cytokine-induced CD40 expression in HUVECs and shows dose-dependency to some degree. It also suggests that ghrelin has a significant immune-regulating effect as well as its anti-inflammatory effect in the cardiovascular system. However, its mechanism, like that of other inflammation regulating effects, is induced by GHSR-1a receptor. Further investigation should be done on the downstream pathways after regulation of CD40/CD40L by ghrelin in the atherosclerosis process. In vivo animal experiments are necessary to identify the role of ghrelin and its receptors involved in the pathogenesis of atherosclerosis. If the involvement of ghrelin in the
